Small-molecule inhibitors of the p53 suppressor HDM2: have protein-protein interactions come of age as drug targets?

Trends Pharmacol Sci. 2004 Jul;25(7):343-6. doi: 10.1016/j.tips.2004.04.011.
No abstract available

Publication types

  • Review

MeSH terms

  • Animals
  • Binding Sites / drug effects
  • Binding Sites / physiology
  • Drug Delivery Systems / methods*
  • Humans
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism*
  • Nuclear Proteins / antagonists & inhibitors*
  • Nuclear Proteins / metabolism*
  • Nuclear Proteins / physiology
  • Protein Binding / drug effects
  • Protein Binding / physiology
  • Proto-Oncogene Proteins / antagonists & inhibitors*
  • Proto-Oncogene Proteins / metabolism*
  • Proto-Oncogene Proteins / physiology
  • Proto-Oncogene Proteins c-mdm2
  • Repressor Proteins / antagonists & inhibitors
  • Repressor Proteins / metabolism
  • Repressor Proteins / physiology
  • Tumor Suppressor Protein p53 / antagonists & inhibitors*
  • Tumor Suppressor Protein p53 / metabolism*

Substances

  • Nuclear Proteins
  • Proto-Oncogene Proteins
  • Repressor Proteins
  • Tumor Suppressor Protein p53
  • MDM2 protein, human
  • Proto-Oncogene Proteins c-mdm2